Compile Data Set for Download or QSAR
maximum 50k data
Found 728 of ki for UniProtKB: P08473
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US10123984, Example 2A | US10744104, Example 2A | ...)
Affinity DataKi:  0.200nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411736(CHEMBL271225)
Affinity DataKi:  0.280nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582847(US11547687, Comparative Compound I | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50614468(CHEMBL5272269)
Affinity DataKi:  0.400nMAssay Description:Binding affinity to neutral endopeptidase (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.501nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617465(US20230285340, Example 5A)
Affinity DataKi:  0.631nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50024101((S)-2-((S)-2-Mercaptomethyl-3-phenyl-propionylamin...)
Affinity DataKi:  0.700nMAssay Description:Inhibition of human recombinant NEP using Suc-Ala-Ala-Phe-AMC as substrate after 30 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411731(CHEMBL257726)
Affinity DataKi:  0.800nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458406((2R,4R)-5-(3-Chlorobiphenyl-4-yl)-2-hydroxy-4-(oxa...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458407(US10744104, Example 5-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US10123984, Example 6A | US10744104, Example 6A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298307(US10123984, Example 8-2 | US10744104, Example 8-2 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298308(US10123984, Example 8-3 | US10744104, Example 8-3 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458416(US10744104, Example 11-2 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582844(US11547687, Comparative Compound G | US20230285340...)
Affinity DataKi:  1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459383(US10759813, Example 18-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459384(US10759813, Example 18-14)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459385(US10759813, Example 18-15)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459386(US10759813, Example 18-16)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459387(US10759813, Example 18-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459388(US10759813, Example 18-19)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459389(US10759813, Example 18-23)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459390(US10759813, Example 18-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459391(US10759813, Example 18-31)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459392(US10759813, Example 18-32)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459393(US10759813, Example 18-34)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459394(US10759813, Example 18-35)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459395(US10759813, Example 18-37)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459396(US10759813, Example 18-38)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459397(US10759813, Example 18-39)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459398(US10759813, Example 18-40)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459399(US10759813, Example 18-41)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459400(US10759813, Example 18-42)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459401(US10759813, Example 18-43)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459402(US10759813, Example 18-44)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459403(US10759813, Example 18-45)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459404(US10759813, Example 18-46)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459405(US10759813, Example 18-47)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459408(US10759813, Example 18-50)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459409(US10759813, Example 19-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459410(US10759813, Example 19-6)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459411(US10759813, Example 19-12)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459412(US10759813, Example 19-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459413(US10759813, Example 19-18)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459414(US10759813, Example 19-19)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459415(US10759813, Example 19-20)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 728 total ) | Next | Last >>
Jump to: